[98] HUMAN PLURIPOTENT STEM CELL DERIVED ASTROCYTES FOR THE TREATMENT OF ALS, AND INSULING SECRETING ISLETS FOR THE TREATMENT OF DIABETES

Michal Izrael[1], Guy Slutsky[1], Arik Hasson[1], Michel Revel[1], Joseph Itskovitz-Eldor[2], Judith Chebath[2], Kfir Molakandov[2], [1] Kadimastem R&d, [2] Kadimastem ltd

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
  Kadimastem (TASE: KDST) develops human pluripotent stem cell-based cell therapies for Amyotrophic Lateral Sclerosis (ALS) and Diabetes. The company's technologies allow expansion and differentiation of stem cells into functional relevant human cells. Kadimastem established a clinical-grade GMP production and is planning to commence a phase I-IIA clinical trial for ALS treatment in Hadassah Medical Center, Jerusalem in H1 2018.

- **Business Strategy**
  Kadimastem applies its technologies towards pre-clinical and clinical trials. Kadimastem plans to generate long-term revenues from cellular therapies for ALS and diabetes that are based on stem cell derived cells and revenues from collaborations with big pharma/biotech and obtaining non-dilutive grants. Kadimastem is actively seeking licensing/purchasing or collaboration opportunities for completing technologies.

- **Core Technology**
  Kadimastem develops platform technologies for 1) large-scale expansion of pluripotent stem cells and 2) direct differentiation into a range of functional human cells according to its unique protocols. Kadimastem's IP covers differentiation into neuroprotective astrocytes and brain myelinating oligodendrocytes, as well as insulin-producing islet-like cells. The value proposition stem from their development as cell therapy for ALS and Diabetes, respectively.

- **Product Profile/Pipeline**
  For ALS (~450,000 patients globally), Kadimastem completed preclinical studies with its stem cell-derived astrocytes (AstroRx) and intends to commence clinical trials by H1-2018. Kadimastem is also conducting pre-clinical studies with its stem cell-derived islet cell product for the treatment diabetes (global >150 million insulin deficient diabetes mellitus (IDDM) patients).

- **What's Next?**
  Kadimastem completed safety, biodistribution & toxicity studies and applied to the IMOH for commencing phase I-IIA clinical trial in Hadassah Medical Center, Jerusalem for ALS treatment. Kadimastem also gives priority to developing its diabetes cell therapy product. In addition, Kadimastem plans also to raise money globally before an IPO in the US.